1. Impact of an oral nutritional supplement enriched in leucine, EPA, DHA, and β-glucans on the increase of muscle mass in patients with cancer and malnutrition: The alisenoc trial
- Author
-
Alfonso Vidal Casariego, Pedro P. García Luna, Francisco Villazón González, Tomás Martín Folgueras, Samara Palma Milla, Juan José López Gómez, Irene González Navarro, Alicia Calleja Fernández, Tamara Casañas Quintana, Bricia López Plaza, and Daniel A. de Luis Román
- Subjects
Cancer ,Disease-related malnutrition ,Oral nutritional supplement ,Leucine ,Muscle mass ,Omega-3 ,Nutrition. Foods and food supply ,TX341-641 - Abstract
Methods: A randomized, double-blind, parallel-group, controlled, multicenter clinical trial was conducted in patients with cancer and malnutrition during outpatient treatment. Patients were randomized to receive either a specific high-calorie, high-protein ONS enriched with leucine, EPA, DHA, and β-glucans or an isocaloric, isonitrogenous standard ONS for eight weeks. Malnutrition was diagnosed using the SGA and body composition was evaluated using bioimpedance. Results: 57 patients were recruited and 37 completed the intervention period. After the nutritional intervention, patients who received the enhanced-ONS showed a significant increase in muscle mass, which was not detected with the standard ONS [1.92 (4.31) kg vs −0.68 (1.45) kg); p = 0.009)], and there was no significant reduction in the percentage of patients with severe and moderate malnutrition. Conclusion: An enhanced ONS enriched in EPA, DHA, leucine, and β-glucans increases muscle mass and could promote nutritional and functional status recovery in patients with cancer and malnourishment.Trial registration: NCT04184713.
- Published
- 2023
- Full Text
- View/download PDF